Press Releases

WATERTOWN, Mass. , Sept. 12, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its fourth quarter and fiscal year

WATERTOWN, Mass. , Sept. 01, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for treating eye diseases, today announced its financial results for the fourth quarter and fiscal year 2016 will be

U.S. and foreign patents for bioerodible Medidur™, new smaller needle Medidur injector and Tethadur™

WATERTOWN, Mass. , Aug. 15, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that Dr. Glenn J. Jaffe , Robert Machemer Professor of Ophthalmology at Duke University School of

Results to Form Part of Planned Applications for Marketing Approvals in EU and US

Industry Veteran Brings Over 25 Years of Pharmaceutical and Drug Development Experience

WATERTOWN, Mass. and NEW YORK , Aug. 01, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for eye diseases, and Hospital for Special Surgery (HSS), America's leading specialty hospital devoted to orthopedics and

Incremental Risk of Elevated IOP Relative to Control Decreases Through Last Follow-up Visit

Data Presented at 2016 Annual Meeting & Exposition of the Controlled Release Society

Plan to Facilitate Product Development and Reduce Operating Expenses

Study Results Showing No Recurrence of Disease and Statistically Significant Improvement in Visual Acuity to be Published in Ophthalmology

WATERTOWN, Mass. , July 08, 2016 (GLOBE NEWSWIRE) -- pSivida Corp (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that pSivida's Dr. Catherine Kelly will present a poster and oral presentation on "The Controlled

Promising Results for Potential Sustained Treatment of Wet AMD Using a TKI

WATERTOWN, Mass. , May 05, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its third fiscal quarter ended March 31,

WATERTOWN, Mass. , May 04, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that Dr. Paul Ashton , president and CEO, will present "Changing the Treatment Paradigm

WATERTOWN, Mass. , May 02, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA),  a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the European Commission granted orphan medicinal product designation to Medidur™ for

WATERTOWN, Mass. , April 27, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that its financial results for the third quarter of fiscal year 2016 will be released after

WATERTOWN, Mass. , March 24, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that the company will be presenting at the Sidoti Spring 2016 Emerging Growth Convention at

Small Average Increase in IOP Relative to Control Comparable Percentage Treated with Eye Drops for Elevated IOP WATERTOWN, Mass. , March 15, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye

WATERTOWN, Mass. , Feb. 08, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV), (ASX:PVA),  a leader in the development of sustained release drug delivery products for treating eye diseases, today provided a Company update and announced financial results for its second fiscal quarter ended